Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia

Leukemia

Volumn 31, Issue 5, 2017, Pages 1059-1068

  Khan, N ^a   Hills, R K ^b   Virgo, P ^c   Couzens, S ^b   Clark, N ^a   Gilkes, A ^b   Richardson, P ^a   Knapper, S ^b   Grimwade, D ^d   Russell, N H ^e   Burnett, A K ^b   Freeman, S D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c NORTH BRISTOL NHS TRUST   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CORE BINDING FACTOR; GEMTUZUMAB OZOGAMICIN; AMINOGLYCOSIDE; BIOLOGICAL MARKER; CD33 PROTEIN, HUMAN; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE MYELOID LEUKEMIA; ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; GENETIC ASSOCIATION; HUMAN; INDUCTION CHEMOTHERAPY; INTERMEDIATE RISK PATIENT; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; AGE; DOSE RESPONSE; LEUKEMIA, MYELOID, ACUTE; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; SIALIC ACID BINDING IG-LIKE LECTIN 3; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84995370882     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.309     Document Type: Conference Paper

References (26)

1. Rashidi A, Walter RB. Antigen-specific immunotherapy for acute myeloid leukemia. Expert Rev Hematol 2016; 9: 335-350.
2. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29: 369-377.
3. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30: 3924-3931.
4. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013; 121: 4854-4860.
5. Delaunay J, Recher C, Pigneux A, Witz F, Vey N, Blanchet O et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation: results of the GOELAMS AML 2006 IR study. Blood (ASH annual meeting abstracts) 2011; 118, abstr 79.
6. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN et al. Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379: 1508-1516.
7. Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf SH, Othus M et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014; 15: 986-996.
8. Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 2014; 32: 3021-3032.
9. Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R et al. CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children's Oncology Group Trial AAML0531. J Clin Oncol 2016; 34: 747-755.
10. Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A et al. Impact of blast CD33 expression on the effect of gemtuzumab ozogamicin (GO) in adult acute myeloid leukemia (AML): an ALFA-0701 study. Blood 2016; 127: 2157-2160.
11. Pollard J, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood 2012; 119: 3705-3711.
12. Ehninger A, Kramer M, Röllig C, Thiede C, Bornhauser M, von Bonin M et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J 2014; 4: e218.
13. 2 in AML induction: results from the UK NCRI AML 17 trial in 1206 patients. Blood 2015; 125: 3878-3885.
14. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123-4131.
15. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
16. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005; 105: 1295-1302.
17. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109: 4168-4170.
18. Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol 2016; 34: 972-979.
19. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010; 28: 275-280.
20. van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005; 11: 6520-6527.
21. Walter RB, Appelbaum FR, Estey EH, Berstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012; 119: 6198-6208.
22. Jawad M, Seedhouse C, Mony U, Grundy M, Russell N, Pallis M. Analysis of factors that affect in vitro chemosensitivity of leukemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia. Leukemia 2010; 24: 74-80.
23. 2 in the NCRI AML17 Trial. Haematologica 2016; 101: 724-731.
24. Paubelle E, Marceau A, Zylbersztejn F, Dussiot M, Moura IC, Cornillet-Lefebvre P et al. HFE gene mutation status predicts response to gemtuzumab ozogamicin in AML. Blood (ASH annual meeting abstracts) 2015; 126, abstr 1307.
25. Stein EM, Tallman MS. Emerging therapeutic drugs for AML. Blood 2016; 127: 71-78.
26. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H et al. SGNCD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013; 122: 1455-1463.